ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection

Anticancer medicine ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection available upon request. To get best price in india, Call 9811747774 or Email info@medvitaz.com to discuss advanced treatments with Breast Cancer Specialists in India without travel. We help you to get genuine, affordable and assurance of delivery of approved medicines for Breast Cancer.
Category: .

ENHERTU (fam-trastuzumab deruxtecan-nxki) injection

INDICATIONS AND USAGE
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DOSAGE FORMS & STRENGTHS
For injection: 100 mg lyophilized powder in a single-dose vial
Manufactured By: Daiichi Sankyo, Inc.
Prescribing Information URL: Click Here

Anticancer drugs available upon request. To get best price of ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection in india, Call 9811747774 or Email info@medvitaz.com to discuss advanced treatments with Breast Cancer Specialists in India without travel.

Trastuzumab deruxtecan also known as fam-trastuzumab deruxtecan and sold under the brand name Enhertu, is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan). It was approved for use in the United States in December 2019.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.